FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3022105304> ?p ?o ?g. }

• W3022105304 endingPage "e204079" @default.
• W3022105304 startingPage "e204079" @default.
• W3022105304 abstract "Every year, influenza vaccines are administered to millions of people worldwide to reduce morbidity and mortality from influenza. As new vaccine formulations are increasingly used, monitoring and comparing safety, in addition to vaccine effectiveness, in target populations are essential.To assess the postmarketing safety profile of 2018 Southern Hemisphere influenza vaccines, particularly 2 new enhanced trivalent inactivated influenza vaccines: an adjuvanted trivalent inactivated influenza vaccine (aIIV3) and high-dose trivalent inactivated influenza vaccine (HD-IIV3), among Australian individuals 65 years or older.This cohort study used solicited short message service-based self-reported survey data on adverse events occurring within 3 to 5 days after receipt of an influenza vaccination. Participants included individuals 65 years or older who received routinely recommended influenza vaccines at 1 of 265 sentinel immunization sites, including primary care, hospital, and community-based clinics, participating in Australia's AusVaxSafety active vaccine safety surveillance system from April 1 to August 31, 2018. Data were analyzed from September 1, 2018, to June 30, 2019.Any licensed 2018 influenza vaccine administered in clinical practice.Rates (overall, by brand, and by concomitant vaccine receipt) of adverse events, including medical attendance as a proxy for serious adverse events.Of 72 013 individuals 65 years or older who received an influenza vaccine in 2018, 50 134 individuals (69.6%) responded to the initial survey regarding adverse events experienced after vaccination (median [interquartile range] age, 71 [68-76] years; 27 056 [54.0%] women). Most individuals received an enhanced trivalent inactivated influenza vaccine, including 28 003 individuals (55.9%) who received aIIV3 and 19 306 individuals (38.5%) who received HD-IIV3; 2208 individuals (4.4%) received a quadrivalent inactivated influenza vaccine. Individuals who received HD-IIV3 reported significantly higher rates of any adverse event compared with individuals who received aIIV3 (1716 individuals [8.9%] vs 1796 individuals [6.4%]; P < .001) as well as specific adverse events, including fever (195 individuals [1.1%] vs 164 individuals [0.6%]; P < .001), injection site pain (383 individuals [2.1%] vs 350 individuals [1.3%]; P < .001), and injection site swelling or redness (256 individuals [1.4%] vs 248 individuals [0.9%]; P < .001). Adverse event rates reported by those receiving any quadrivalent inactivated influenza vaccine were similar to rates reported by those receiving aIIV3. Rates of medical care seeking for adverse events associated with aIIV3 and HD-IIV3 were low and comparable (80 individuals [0.3%] vs 56 individuals [0.3%]; P = .91).The findings of this large-scale participant-based postmarketing assessment of the safety of 2 new enhanced influenza vaccines used in individuals 65 years or older provide reassuring near-real-time and cumulative data to inform and support confidence in ongoing vaccine use." @default.
• W3022105304 created "2020-05-13" @default.
• W3022105304 creator A5013315640 @default.
• W3022105304 creator A5027256217 @default.
• W3022105304 creator A5029896402 @default.
• W3022105304 creator A5049164171 @default.
• W3022105304 creator A5054461236 @default.
• W3022105304 creator A5076043439 @default.
• W3022105304 creator A5090422411 @default.
• W3022105304 date "2020-05-05" @default.
• W3022105304 modified "2023-10-15" @default.
• W3022105304 title "Comparative Postmarket Safety Profile of Adjuvanted and High-Dose Influenza Vaccines in Individuals 65 Years or Older" @default.
• W3022105304 cites W1631728354 @default.
• W3022105304 cites W1966453753 @default.
• W3022105304 cites W1973905472 @default.
• W3022105304 cites W1982855609 @default.
• W3022105304 cites W1994019765 @default.
• W3022105304 cites W1999067882 @default.
• W3022105304 cites W2013020600 @default.
• W3022105304 cites W2017044611 @default.
• W3022105304 cites W2017740462 @default.
• W3022105304 cites W2036925392 @default.
• W3022105304 cites W2042217493 @default.
• W3022105304 cites W2053330025 @default.
• W3022105304 cites W2077434663 @default.
• W3022105304 cites W2079137826 @default.
• W3022105304 cites W2085044772 @default.
• W3022105304 cites W2107860697 @default.
• W3022105304 cites W2109801797 @default.
• W3022105304 cites W2164949714 @default.
• W3022105304 cites W2168805652 @default.
• W3022105304 cites W2323815977 @default.
• W3022105304 cites W2326927218 @default.
• W3022105304 cites W2417739024 @default.
• W3022105304 cites W2527614013 @default.
• W3022105304 cites W2554526044 @default.
• W3022105304 cites W2581492029 @default.
• W3022105304 cites W2583056663 @default.
• W3022105304 cites W2620761451 @default.
• W3022105304 cites W2767761062 @default.
• W3022105304 cites W2785073138 @default.
• W3022105304 cites W2847695165 @default.
• W3022105304 cites W2897012863 @default.
• W3022105304 cites W2905893134 @default.
• W3022105304 cites W2913937433 @default.
• W3022105304 cites W2997183251 @default.
• W3022105304 cites W4239223728 @default.
• W3022105304 cites W4240480386 @default.
• W3022105304 cites W4255438076 @default.
• W3022105304 cites W4256111822 @default.
• W3022105304 cites W4298373463 @default.
• W3022105304 cites W52213227 @default.
• W3022105304 doi "https://doi.org/10.1001/jamanetworkopen.2020.4079" @default.
• W3022105304 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7201308" @default.
• W3022105304 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32369177" @default.
• W3022105304 hasPublicationYear "2020" @default.
• W3022105304 type Work @default.
• W3022105304 sameAs 3022105304 @default.
• W3022105304 citedByCount "12" @default.
• W3022105304 countsByYear W30221053042021 @default.
• W3022105304 countsByYear W30221053042022 @default.
• W3022105304 countsByYear W30221053042023 @default.
• W3022105304 crossrefType "journal-article" @default.
• W3022105304 hasAuthorship W3022105304A5013315640 @default.
• W3022105304 hasAuthorship W3022105304A5027256217 @default.
• W3022105304 hasAuthorship W3022105304A5029896402 @default.
• W3022105304 hasAuthorship W3022105304A5049164171 @default.
• W3022105304 hasAuthorship W3022105304A5054461236 @default.
• W3022105304 hasAuthorship W3022105304A5076043439 @default.
• W3022105304 hasAuthorship W3022105304A5090422411 @default.
• W3022105304 hasBestOaLocation W30221053041 @default.
• W3022105304 hasConcept C119060515 @default.
• W3022105304 hasConcept C126322002 @default.
• W3022105304 hasConcept C133239900 @default.
• W3022105304 hasConcept C147483822 @default.
• W3022105304 hasConcept C197934379 @default.
• W3022105304 hasConcept C203014093 @default.
• W3022105304 hasConcept C22070199 @default.
• W3022105304 hasConcept C2780689484 @default.
• W3022105304 hasConcept C2780801004 @default.
• W3022105304 hasConcept C71924100 @default.
• W3022105304 hasConceptScore W3022105304C119060515 @default.
• W3022105304 hasConceptScore W3022105304C126322002 @default.
• W3022105304 hasConceptScore W3022105304C133239900 @default.
• W3022105304 hasConceptScore W3022105304C147483822 @default.
• W3022105304 hasConceptScore W3022105304C197934379 @default.
• W3022105304 hasConceptScore W3022105304C203014093 @default.
• W3022105304 hasConceptScore W3022105304C22070199 @default.
• W3022105304 hasConceptScore W3022105304C2780689484 @default.
• W3022105304 hasConceptScore W3022105304C2780801004 @default.
• W3022105304 hasConceptScore W3022105304C71924100 @default.
• W3022105304 hasIssue "5" @default.
• W3022105304 hasLocation W30221053041 @default.
• W3022105304 hasLocation W30221053042 @default.
• W3022105304 hasLocation W30221053043 @default.
• W3022105304 hasLocation W30221053044 @default.
• W3022105304 hasOpenAccess W3022105304 @default.
• W3022105304 hasPrimaryLocation W30221053041 @default.

• next